Indium (111In) igovomab

Last updated January 30, 2026

Indium (¹¹¹In) igovomab
Monoclonal antibody
Type	F(ab')₂ fragment
Source	Mouse
Target	CA-125
Clinical data
ATC code	none
Identifiers
CAS Number	171656-50-1 ^N
ChemSpider	none
UNII	GBK36SFC9C
^NY (what is this?) (verify)

Indium (¹¹¹In) igovomab (trade name Indimacis-125) was a mouse monoclonal antibody for the diagnosis of ovarian cancer.^{[ citation needed ]}

Linked to the chelating agent DTPA and labelled with Indium-111, it was used for imaging (radio-immuno scintigraphy) of the cancer.^{[ citation needed ]} The drug is no longer available.^[1]^[2]

References

↑ Google books: Handbook of Therapeutic Antibodies, vol. 3
↑ "Biopharma: indium (111 In) igovomab - Indimacis 125". Archived from the original on 2020-05-26. Retrieved 2009-09-24.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab ^§ Amivantamab (+hyaluronidase) Ascrinvacumab ^§ Balstilimab ^† Botensilimab Cixutumumab ^§ Conatumumab ^§ Cosibelimab Daratumumab Drozitumab ^§ Duligotumab ^§ Dusigitumab ^§ Enfortumab vedotin Enoticumab ^§ Figitumumab ^§ Flanvotumab ^§ Ganitumab ^† Glembatumumab vedotin ^† Intetumumab ^§ Ipilimumab Iratumumab ^§ Istiratumab Icrucumab ^§ Lexatumumab ^§ Linvoseltamab Lucatumumab ^§ Mapatumumab ^§ Narnatumab ^§ Necitumumab Nesvacumab ^§ Nivolumab ^# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab ^† Panitumumab Patritumab ^§ Pritumumab ^§ Radretumab ^§ Ramucirumab Rilotumumab ^† Robatumumab ^§ Seribantumab ^§ Sugemalimab Tarextumab ^§ Tisotumab vedotin Teprotumumab ^† Tovetumab ^§ Vantictumab ^§ Votumumab ^§ Zalutumumab ^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab ^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab ^§ Bavituximab ^§ Brentuximab vedotin Carotuximab ^† Cetuximab Derlotuximab biotin ^§ Dinutuximab Ecromeximab ^§ Ensituximab ^§ Futuximab ^§ Girentuximab ^† Indatuximab ravtansine ^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab ^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab ^§ Alemtuzumab Atezolizumab (+hyaluronidase) Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine ^§ Brontictuzumab ^§ Cantuzumab mertansine ^§ Cantuzumab ravtansine ^§ Cirmtuzumab Citatuzumab bogatox ^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab ^§ Demcizumab ^§ Dalotuzumab ^§ Datopotamab deruxtecan Denintuzumab mafodotin ^§ Elotuzumab Emactuzumab Emibetuzumab ^§ Enoblituzumab ^§ Epcoritamab Etaracizumab ^§ Farletuzumab ^§ Ficlatuzumab ^§ Flotetuzumab ^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab ^§ Inotuzumab ozogamicin Labetuzumab ^§ Lifastuzumab vedotin ^§ Lintuzumab ^§ Lorvotuzumab mertansine ^§ Lumretuzumab ^§ Matuzumab ^§ Milatuzumab ^§ Naxitamab Nimotuzumab ^† Obinutuzumab Ocaratuzumab ^§ Odronextamab Otlertuzumab ^§ Onartuzumab ^§ Oportuzumab monatox ^† Parsatuzumab ^§ Pembrolizumab ^# (+berahyaluronidase alfa) Penpulimab Pertuzumab Pinatuzumab vedotin ^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine ^† Sacituzumab govitecan Sibrotuzumab ^§ Simtuzumab ^§ Sofituzumab vedotin ^§ Tacatuzumab tetraxetan ^§ Tigatuzumab ^§ Trastuzumab ^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin ^§ Vandortuzumab vedotin ^§ Vanucizumab ^§ Veltuzumab ^§ Vorsetuzumab mafodotin ^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab ^§
Chimeric + humanized	Depatuxizumab mafodotin ^† Duvortuxizumab Ontuxizumab ^§

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

This monoclonal antibody–related article is a stub. You can help Wikipedia by adding missing information.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.